09.06.2017
VALBIOTIS will present the results of its Phase I/II clinical study on the active ingredient of Valedia®, TOTUM-63, during the 77th Scientific Sessions of the American Diabetes Association.
Download
24.04.2017
Sébastien PELTIER, CEO of VALBIOTIS, presents his vision of diabetes-free world at l’Echappée Volée
Download
12.04.2017
Two partnership agreements to assess the effects of TOTUM-63, the active ingredient Valedia®, on intestinal microbiota
Download
